Corey J. Langer M.D.

Bio

When it comes to mesothelioma and thoracic cancer as a whole, Corey J. Langer, M.D., director of Thoracic Oncology at the University of Pennsylvania Abramson Cancer Center, has accomplished a remarkable body of experience in treating patients. But in his role as a professor of medicine in the Hematology-Oncology Division, Langer has also been at the forefront of influential research in these potentially life-threatening conditions.

Langer's research has centered on the areas of salvage therapy (treatments given when standard treatments fail) and concurrent chemotherapy and radiation regimens. Many of these treatment options focus on the elderly and those with compromised functional status.

Langer participated in the groundbreaking Canadian JBR.10 study, one of the first to look at adjuvant treatment in the elderly.

In an interview with Lung Cancer Update, Langer said that squamous cell types in the elderly are "probably a result of the use of cigarettes." The upside is that "the elderly had a significant survival benefit."

Langer is the chair of the Medical Oncology Committee of the Radiation Therapy Oncology Group (RTOG), a national organization that seeks to conduct clinical investigations and further radiation therapy. Langer has significantly contributed to the treatment of mesothelioma and lung cancer patients through multiple memberships in a variety of associations and committees.

Learn More about Mesothelioma Treatments

The Mesothelioma Center developed a comprehensive packet of information on mesothelioma and other asbestos-related diseases. This free packet was designed to help patients understand the many facets of mesothelioma. It provides essential information about the different types of this rare cancer and the variety of treatment options for managing the disease. This complimentary packet also discusses the causes and effects of mesothelioma and provides information about financial assistance that can help cover medical costs. Click here to request a copy of this free care packet.

Publications

Langer has contributed three articles to modern mesothelioma literature; two discussed the combination of pemetrexed and gemcitabine and the other explored the restrictive limits for non-small cell lung cancer patients who are looking to access treatment.